BHC News and Press, Bausch Health Companies Inc. From 05/22/24

2024-05-22 16:31:48 ET Summary Bausch + Lomb, a spin-off from Bausch Health, has shown solid performance with revenues of $4.1bn in 2023 and a narrowing net loss of $(260m). The company's Q1 2024 report shows growth in all segments, including Vision Care, Surgical, and Pharmaceuti...

LAVAL, QC / ACCESSWIRE / May 17, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod as treatment for active ulcerative colitis (UC). ...

LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its 2024 annual meeting of shareholders. Annual Meeting Results The 10 directors nominated at the Company's 2024 annual meeting of shareholders held on May 14, 2024, were e...

2024-05-14 16:51:58 ET More on Bausch Health Companies Why Bausch Health Stock Plunged After Posting First Quarter 2024 Results Bausch Health Companies (BHC) Q1 2024 Earnings Call Transcript Bausch Health Companies Inc. 2024 Q1 - Results - Earnings Call Presentation ...

LAVAL, QC / ACCESSWIRE / May 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigation with Norwich Pharmaceuticals, Inc. With respect to the April 11, 2024, decision of the US C...

Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adults Overt Hepatic Encephalopathy is caused by cirrhosis of the liver As complications from chronic liver disease increase, recognizing OHE is critical so that patients can work with t...

2024-05-07 09:15:00 ET Summary Bausch Health Companies stock experienced a significant drop after posting its first-quarter results, missing expectations by 13 cents. The company's debt maturity profile raises concerns for investors, with a large amount of debt maturing in 2025 an...

2024-05-06 11:12:29 ET More on Bausch + Lomb Bausch + Lomb Corporation (BLCO) Q1 2024 Earnings Call Transcript Bausch + Lomb Corporation (BLCO) Q4 2023 Earnings Call Transcript Bausch + Lomb Corporation 2023 Q4 - Results - Earnings Call Presentation Bausch + ...

2024-05-06 10:47:03 ET Bausch Health Companies Inc (BHC) BHC is trading DOWN for the last 4 days, and it at trading at $7.69 with volume of 1,380,917 and a one day change of $-0.14 (-1.73%). Bausch Health Companies Inc has a 52-week low of 5.57 and a 52-week high of $11.46. The busi...

2024-05-02 18:43:30 ET Eyecare specialist Bausch Health Companies (NYSE: BHC) wasn't a clear winner on the stock exchange Thursday, to put it charitably. After unveiling its latest earnings report it was met with a sell-off, as investors drove its share price down by over 7%. That w...